Redpin Therapeutics, a preclinical stage gene therapy company developing proprietary ion channel-based targeted cell therapies that address diseases of the nervous system, announced that it had secured $15.5 million in the initial closing of its Series A financing round.
This fundraise will enable Redpin Therapeutics to advance the development of its groundbreaking ultra-potent ion channel-based chemogenetics platform to address such neurological disorders as epilepsy, neuropathic pain and Parkinson’s disease.
Repin’s approach consists in designing chimeric ligand-gated ion channels as targeted cell therapies to selectively stimulate or inhibit dysfunctional neuronal circuits implicated in a given disease.
